Skip to Main Content
<< Back | Return to Main COMAR Search Page

9 records match your request.

FileAbstract
10.62.23.00.htm 10.62.23.00. Title 10 MARYLAND DEPARTMENT OF HEALTH Subtitle 62 NATALIE LAPRADE MEDICAL CANNABIS COMMISSION Chapter 23 Medical Cannabis Concentrates and Medical Cannabis-Infused Products Authority: Health-General Article, §13-3301, 13-3302, 13-3309, and 13-3311, Annotated Code of Maryland
10.62.23.01.htm 10.62.23.01. 01 Definitions.. A. In this chapter, the following terms have the meanings indicated.. B. Terms Defined.. 1) “License” means a license issued by the Commission to operate as a processor.. 2) “Licensee” means a licensed processor.. 3) “Tincture” means a cannabis-infused solution derived either directly from the cannabis plant or from a processed cannabis extract and typically combined with alcohol, glycerin, or vegetable oils.
10.62.23.02.htm 10.62.23.02. 02 Controls for Processing of Medical Cannabis Concentrates and Medical Cannabis-Infused Products.. A. A licensed processor of medical cannabis concentrates and medical cannabis-infused products shall:1) Develop standard operating procedures, good manufacturing practices, and a training plan before producing medical cannabis concentrates and medical cannabis-infused products;2) Require that any person involved in processing medical cannabis concentrates and medical cannabis
10.62.23.03.htm 10.62.23.03. 03 Independent Testing Laboratory Selection and Responsibility.. Upon successful completion of a validation process, the licensee shall use an independent testing laboratory:A. That has adopted a standard operating procedure to test medical cannabis and medical cannabis concentrate that is approved by an accreditation body that is a signatory to the International Laboratory Accreditation Cooperation (ILAC) Mutual Recognition Arrangement;B. To have an agent of th
10.62.23.04.htm 10.62.23.04. 04 Contents of Certificate of Analysis.. A. An independent testing laboratory shall issue a certificate of analysis for each lot, with supporting data, to report:1) Whether the chemical profile of the lot conforms to the specifications for the lot for the following compounds:a) ?9-Tetrahydrocannabinol (THC). b) Tetrahydrocannabinolic Acid (THCA). c) Cannabidiol (CBD). d) Cannabidiolic Acid (CBDA). e) The terpenes described in the most current version of the cannabis Inflo
10.62.23.05.htm 10.62.23.05. 05 Licensed Processor Determination That a Lot May be Released.. A. If a licensed processor, upon review of the certificate of analysis, determines that a lot meets the specification for the product, the licensed processor may:1) Assign an expiration date to the lot;. 2) Release the lot for distribution; and. 3) Revise the status of the lot in the inventory control.. B. If a licensed processor receives test results that the lot does not meet specifications, the lice
10.62.23.06.htm 10.62.23.06. 06 Stability Testing and Retention Sampling.. A. A licensee shall provide a sample from each released lot to an independent testing laboratory sufficient to perform stability testing at 6-month intervals to:1) Ensure product potency and purity; and. 2) Provide support for expiration dating.. B. A licensee shall retain a sample from each released lot:. 1) Sufficient to provide for follow-up testing if necessary; and.
10.62.23.07.htm 10.62.23.07. 07 Report of Products Offered for Distribution.. A licensee shall submit to the Commission within 30 days following the end of a quarter a list of the products and the products’ specifications that the licensee offered for distribution in the quarter.
10.62.23.9999.htm 10.62.23.9999. Administrative History Effective date: September 14, 2015 (42:18 Md. R. 1176).
<< Back | Return to Main COMAR Search Page